PDE5 inhibitors, by stimulating the GCs pathways, show a relatively selective vasodilator activity to the pulmonary arteries, and thus are one of the basic groups used in pharmacotherapy of pulmonary hypertension. Here, PDE5A is linked to pulmonary hypertension.